Shares of Curis CRIS fell 0.88% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 42.11% year over year to ($0.11), which beat the estimate of ($0.13).
Revenue of $2,742,000 decreased by 3.99% from the same period last year, which beat the estimate of $2,570,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Curis hasn't issued any revenue guidance for the time being.
How To Listen To The Conference Call
Date: Nov 10, 2020
Time: 04:30 PM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/1827/38600
Recent Stock Performance
52-week high: $3.59
Company's 52-week low was at $0.62
Price action over last quarter: down 15.11%
Company Profile
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
